Dyson N, Bernards R, Friend S, Gooding L, Hassel J, Major E, Pipas
J, Prives C, Van Dyke T, & Harlow E. (1990) The large antigens
of many polyma viruses are able to form complexes with the retinoblastoma
protein. J.Virol. 64:1353-1356.
Koretsky A, Brosnan J, Chen LH, and Van Dyke TA. (1990) NMR detection
of creatine kinase expressed in liver oftransgenic mice: Determination
of free ADP levels. Proc. Natl. Acad. Sci. USA 87:3112-3116.
Brosnan J, Chen L, Van Dyke T, and Koretsky AP. (1990) Free ADP
levels in transgenic mouse liver expressing creatine kinase: effects
of enzyme activity, phosphagen type and substrate concentration.
J. Biol. Chem. 265:20849-20855.
Brosnan J, Chen L, Wheeler CE, Van Dyke T, and Koretsky A. (1991)
Phosphocreatine protects hepatic ATP from a fructose load in transgenic
mouse liver expressing creatine kinase. Am. J. Physiol. 260:1191-1200.
Symonds H, Chen J, and Van Dyke T. (1991) Complex formation between
the lymphotropic papovavirus large tumor antigen and the tumor
suppressor protein, p53. J. Virol. 65:5417-5424.
Page
Van Dyke, Terry A., Chen J and Van Dyke T. (1991) Uniform cell-autonomous
tumorigenesis of the choroid plexus by papovaviraus large T antigens.
Mol. Cell. Biol. 11:5968-5976.
Chen J, Tobin G, Pipas J, and Van Dyke TA. (1992) T antigen mutant
activities in vivo: roles of p53 and pRB binding in tumorigenesis
of the choroid plexus. Oncogene. 7:1167-1175.
Van Dyke TA. (1993) Tumors of choroid plexus, In: Molecular Genetics
of Nervous System Tumors, eds. Levine and Schmidek, publisher
Wiley & Sons,
p287-301.
Symonds H, McCarthy S, Chen J, Pipas JM, and Van Dyke T. (1993)
Use of transgenic mice reveals cell-specific transformation by
an SV40 T antigen amino-terminal mutant. Mol. Cell. Biol. 13:3255-3265.
Van Dyke T. (1994) Analysis of viral-host protein interactions
and tumorigenesis in transgenic mice. Semin. in Cancer Biol., 5:47-60.
McCarthy SA, Symonds HS, and Van Dyke T. (1994) Regulation of
apoptosis in transgenic mice by SV40 T antigen-mediated inactivation
of p53. Proc. Natl. Acad. Sci. USA. 91:3979-3983.
Sáenz Robles MT, Symonds HS, Chen J, and Van Dyke T. (1994)
Induction versus progression of brain tumor development: Differential
functions of the pRB- and p53-targeting domains of SV40 T antigen.
Mol. Cell. Biol. 14:2686-2698.
Symonds H, Krall L, Remington L, Sáenz Robles MT, Lowe
S, Jacks T, and Van Dyke T. (1994) p53 dependent apoptosis suppresses
tumor growth and progression in vivo. Cell, 78:703-711.
Symonds H, Krall L, Remington L, Sáenz Robles MT, Lowe
S, Jacks T, and Van Dyke T. (1994) p53-dependent apoptosis in
vivo: Impact of p53 inactivation in tumorigenesis. Cold Spring
Harb.
Symp. Quant. Biol. 49:247-257.
Wu H, Wade M, Krall L, Grisham J, Xiong Y, and Van Dyke T. (1996)
Targeted in vivo expression of the cyclin-dependent kinase inhibitor
p21 halts hepatocyte cell-cycle progression, postnatal liver development,
and regeneration. Genes and Dev. 10:245-260.
Bowman T, Symonds H, Gu L, Oren M, and Van Dyke T. (1996) Tissue-specific
inactivation of p53 tumor suppression in the mouse. Genes and Dev.
10:826-835.
Yin C, Knudson M, Korsmeyer S, and Van Dyke T. (1997) Bax suppresses
tumorigenesis and stimulates apoptosis in vivo. Nature 385:637-640.
Li J, Witte DP, Van Dyke T, Askew DS. (1997) Expression of the
putative protooncogene His-1 in normal and neoplastic tissues.
Am. J. of Pathology 150:1297-1305.
Patrick T, Dranz D, Van Dyke T, and Edward R. (1997) Folate receptors
as potential therapeutic targets in choroid plexus tumors of SV11
transgeneic mice. J. of Neuro-Oncology 32:111-123.
Pan H, Yin C, and Van Dyke T. (1997) Apoptosis and cancer mechanisms.
Cancer Surveys 29:305-327.
Liao M-J, Zhang X-X, Hill R, Gao J, Qumsiyeh MB, Nichols W, and
Van Dyke T. (1998) No requirement for V(D)J recombination in p53-deficient
thymic lymphoma. Mol. Cell. Biol. 18:3495-3501.
Pan H, Yin C, Yamaskai L. Dyson N, Harlow E, and Van Dyke T. (1998)
Key roles for E2F1 in p53-dependent apoptosis and cell cycle regulation
within developing tumors. Mol. Cell. 2:283-292.
Liao M-J, Yin C, Barlow C, Wynshaw-Boris A, and Van Dyke T. (1999)
Atm is dispensable for p53 apoptosis and tumor suppression when
signaled by cell cycle dysfunction. Mol. Cell. Biol. 19:3095-3102.
Liao M-J and Van Dyke TA. (1999) Critical role for Atm in suppressing
VDJ recombination-driven thymic lymphoma, Genes and Dev. 13:1246-1250
de La Coste A., Mignon A, Fabre M, Gilbert E, Porteu A, Van Dyke
T, Kahn A, and Perret C (1999) Paradoxical inhibition of c-myc-induced
carcinogenesis by Bcl-2 in transgenic mice. Cancer Research 59:5017-5022.
Salganik RI, Albright CD, Rodgers J, Kim J, Zeisel SH, Sivanshenskiy
MS, and Van Dyke TA (2000) Antioxidant depletion: Enhancement of
apoptotic tumor cell death and inhibition of brain tumor growth
in transgenic mice. Carcinogenesis, 21: 909-914.
Lu, X., G. Magrane, D.N.Louis, J. Gray, and T. Van Dyke (2001)
Selective inactivation of p53 facilitates mouse epithelial tumor
progression without chromosomal instability, Mol. and Cell Biol.,
21:6017-6030
Garciduenas L., Alcaraz, A., Salazar G., Tascareno A., Garcia
R., Osnaya N., Calderon A., Devlin R. and Van Dyke TA (2001)
Nasal Biopsies of Children Exposed to Air Polluntants. Toxicologic
Pathology, 29:558-564.
Tolbert D, Lu X, Yin C, Tantama, M and Van Dyke TA (2002) p19arf
is Dispensable for Oncogenic Stress-Induced p53-dependent Apoptosis
and Tumor Suppression in vivo. Mol. Cell Biol., 22:370-377.
Perkins EJ, Nair A, Cowley DO, Van Dyke T., Chang Y. Ramsden DA
(2002) Sensing of Intermediates in V(D)J recombination by
ATM. Genes Dev. 2002 Jan. 15;16:159-64.
Van Dyke, T. and T. Jacks (2002) Cancer Modeling in the Modern
Era: Progress and Challenges. Cell, Vol. 108,135-144,
Xiao A, Wu H, Louis DN, Pandolfi PP, Van Dyke TA. 2002. Astrocyte
inactivation of the pRb pathway predisposes mice to malignant astrocytoma
development that is accelerated by PTEN Mutation. Cancer Cel1,1:157-168.
Weiss, W A, Israel M., Cobbs C., Holland E., James C D, Louis
D N, Marks Cheryl, McClatchey A., Roberts T., Van Dyke T. , Wetmore
C., Chiu I., Giovannini M., Guha A., Higgins R., Marino S., Radovanovic
I., Reilly K., Aldape K. (2002) Neuropathology of genetically engineered
mice. Oncogene. 21;44
Trotman, L., Niki, M., Dotan,Z., Koutcher, J., Di Cristofano,
A, Xiao, A, Khoo, A., Roy-Burman, Greenberg, N. , Van Dyke, T.,
Cordon-Cardo, C. P.P Pandolfi. (2003) PTEN Dose Dictates Cancer
Progression in the Prostate. PloS Biology, 1:385-396
Simin, K. H. Wu, L. Lu, D. Pinkel, D. Albertson, R. Cardiff, and
Van Dyke TA (2004) pRb Inactivation in Mammary Cells Predisposes
to Adenocarcinoma and Reveals Common Mechanisms for Tumor Initiation
and Progression in Divergent Epithelia. PloS Biology, in press
for February 2004
Page
Van Dyke, Terry A.
Submitted or in Preparation:
Xiao A, Di Cristofano, A,, Pandolfi PP, Van Dyke TA. (2004) PTEN
Inactivation Facilitates Progression to High-Grade Tumors by Multiple
Mechanisms and Pathways. Submitted.
Albright C, Shah A, Monson R, Garcia P, Salganik R, and Van Dyke
TA (2004) Dietary Antioxidant Depletion Inhibits Mammary Tumor
Growth and Metastasis in Transgenic Mice (submitted).
Hill, R., Cardiff R, and Van Dyke TA (2003) Inactivation of the
pRb pathway specifically in prostate epithelium induces high grade
PIN and predisposes to carcinoma development in mice. (in preparation).
Yin, C., and Van Dyke, T. (2003) Progression to angiogenesis coincident
with somatic inactivation of p53 in a transgenic brain tumor model
(in preparation).
Zhang L, Allan R, Wu H, and Van Dyke TA (2003) Highly penetrant
diabetes induced by targeted expression of cell cycle inhibitors
in liver and pancreas (in preparation).
